Literature DB >> 35131972

Coronary Endothelial Dysfunction in People Living With HIV Is Related to Body Fat Distribution.

Erin Goerlich1, Michael Schär2, Shashwatee Bagchi3, Alborz Soleimani-Fard1, Todd T Brown4, Sudipa Sarkar4, Gabriele Bonanno1,2, Valerie Streeb1, Gary Gerstenblith1, Patricia Barditch-Crovo5, Robert G Weiss1,2, Allison G Hays1,2.   

Abstract

BACKGROUND: People living with HIV (PLWH) on antiretroviral therapy (ART) are at increased risk of atherosclerotic disease. Abnormal adipose distribution is common in PLWH and may contribute to atherosclerosis. Because coronary artery endothelial function (CEF) is impaired in early atherosclerosis, predicts future cardiovascular events, and is reduced in PLWH, we investigated associations between body fat distribution and CEF in PLWH.
SETTING: Prospective cohort study.
METHODS: PLWH on stable ART underwent MRI to quantify CEF, measured as change in coronary cross-sectional area from rest to that during isometric handgrip exercise, an endothelial-dependent stressor. Abdominal visceral and subcutaneous fat area (axial L4 level) and liver fat fraction were quantified using MRI. Linear regression was used to determine associations between CEF and independent variables.
RESULTS: Among 84 PLWH (52 ± 11 years; 33% women), mean cross-sectional area change was 0.74 ± 11.7%, indicating impaired CEF. On univariable regression analysis, CEF was inversely related to waist circumference (R = -0.31, P = 0.014), hip circumference (R = -0.27, P = 0.037), and subcutaneous fat area (R = -0.25, P = 0.031). We did not observe significant relationships between CEF and liver fat fraction, waist/hip ratio, or visceral fat area. On multivariable regression adjusted for age, sex, and race, CEF was associated with waist circumference, hip circumference, subcutaneous fat, and liver fat fraction.
CONCLUSION: Waist and hip circumference and subcutaneous fat area are associated with impaired CEF, an established metric of abnormal vascular health in PLWH on stable ART, and may contribute to the increased rate of heart disease in this population.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 35131972      PMCID: PMC9203878          DOI: 10.1097/QAI.0000000000002932

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.771


  39 in total

1.  Non-alcoholic fatty liver disease as a determinant of cardiovascular disease.

Authors:  Giovanni Targher
Journal:  Atherosclerosis       Date:  2006-07-07       Impact factor: 5.162

Review 2.  HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity.

Authors:  Steven G Deeks; Andrew N Phillips
Journal:  BMJ       Date:  2009-01-26

Review 3.  Subcutaneous and visceral adipose tissue: structural and functional differences.

Authors:  M Mohsen Ibrahim
Journal:  Obes Rev       Date:  2009-07-28       Impact factor: 9.213

4.  Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy.

Authors:  Judith S Currier; Jens D Lundgren; Andrew Carr; Daniel Klein; Caroline A Sabin; Paul E Sax; Jeffrey T Schouten; Marek Smieja
Journal:  Circulation       Date:  2008-06-19       Impact factor: 29.690

Review 5.  The Fat of the Matter: Obesity and Visceral Adiposity in Treated HIV Infection.

Authors:  Jordan E Lake
Journal:  Curr HIV/AIDS Rep       Date:  2017-12       Impact factor: 5.071

6.  Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity.

Authors:  S R Smith; J C Lovejoy; F Greenway; D Ryan; L deJonge; J de la Bretonne; J Volafova; G A Bray
Journal:  Metabolism       Date:  2001-04       Impact factor: 8.694

Review 7.  Role of endothelial dysfunction in atherosclerosis.

Authors:  Jean Davignon; Peter Ganz
Journal:  Circulation       Date:  2004-06-15       Impact factor: 29.690

8.  MRI estimated changes in visceral adipose tissue and liver fat fraction in patients with obesity during a very low-calorie-ketogenic diet compared to a standard low-calorie diet.

Authors:  G M Cunha; L Lugarino Correa de Mello; K A Hasenstab; L Spina; I Bussade; J Marques Prata Mesiano; W Coutinho; G Guzman; I Sajoux
Journal:  Clin Radiol       Date:  2020-03-20       Impact factor: 2.350

9.  Regional coronary endothelial dysfunction is related to the degree of local epicardial fat in people with HIV.

Authors:  Micaela Iantorno; Sahar Soleimanifard; Michael Schär; Todd T Brown; Gabriele Bonanno; Patricia Barditch-Crovo; Lena Mathews; Shenghan Lai; Gary Gerstenblith; Robert G Weiss; Allison G Hays
Journal:  Atherosclerosis       Date:  2018-08-17       Impact factor: 5.162

10.  A randomized, placebo-controlled, double-blinded clinical trial of colchicine to improve vascular health in people living with HIV.

Authors:  Allison G Hays; Michael Schär; Patricia Barditch-Crovo; Shashwatee Bagchi; Gabriele Bonanno; Joseph Meyer; Yohannes Afework; Valerie Streeb; Samuel Stradley; Shannon Kelly; Nicole M Anders; Joseph B Margolick; Shenghan Lai; Gary Gerstenblith; Robert G Weiss
Journal:  AIDS       Date:  2021-06-01       Impact factor: 4.632

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.